Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Current Hepatology Reports
Published in: Current Hepatology Reports 3/2023

15-07-2023 | Hepatocellular Carcinoma

Magnetic Resonance Imaging-Based Surveillance of Hepatocellular Carcinoma: Current Status and Future Perspectives

Authors: Hyo Jung Park, So Yeon Kim, Young-Suk Lim

Published in: Current Hepatology Reports | Issue 3/2023

Login to get access

Abstract

Purpose of Review

We aimed to introduce various magnetic resonance imaging (MRI)-based hepatocellular carcinoma (HCC) surveillance strategies in high-risk patients from technical to clinical viewpoints and provide guidance on selecting patients who would benefit from MRI-based surveillance.

Recent Findings

MRI has recently gained attention as an HCC surveillance tool due to its superior sensitivity in detecting early-stage HCC over ultrasonography (US). However, complete-sequence contrast-enhanced liver MRI has limitations of long scan time and high cost. Abbreviated MRI (AMRI) utilizes only the essential sequences for detecting HCC and has gained popularity for reduced scan time and cost while maintaining high diagnostic performance. Three AMRI protocols have been proposed, including hepatobiliary-phase, dynamic contrast-enhanced, and non-enhanced AMRI. Herein, technical details, result interpretation, performances based on previous work, ongoing trials, and current issues regarding each MRI protocol are discussed. For maximum benefits of MRI-based surveillance, a risk-stratified approach should be undertaken to select the target population, simultaneously considering cost-effectiveness. MRI-based HCC surveillance can be beneficial for populations whose US examination has inadequate quality. Evidence of cost-effectiveness of MRI-based surveillance for high-risk patients is growing.

Summary

MRI-based surveillance, particularly using AMRI, shows promise as a sensitive and cost-effective approach for early detection of HCC. Tailored approaches that take into account the patient’s HCC risk and the quality of ultrasonographic images can optimize the benefits of MRI-based surveillance. Further research is needed to assess the cost-effectiveness of MRI-based surveillance strategies.
Literature
1.
Llovet JM, Kelley RK, Villanueva A, Singal AG, Pikarsky E, Roayaie S, et al. Hepatocellular carcinoma. Nat Rev Dis Primers. 2021;7:6.PubMedCrossRef
2.
Global Burden of Disease Liver Cancer Collaboration. The burden of primary liver cancer and underlying etiologies from 1990 to 2015 at the global, regional, and national level: results from the Global Burden of Disease Study 2015. JAMA Oncol. 2017;3:1683–91.PubMedCentralCrossRef
3.
Rumgay H, Arnold M, Ferlay J, Lesi O, Cabasag CJ, Vignat J, et al. Global burden of primary liver cancer in 2020 and predictions to 2040. J Hepatol. 2022;77:1598–606.PubMedPubMedCentralCrossRef
4.
Serper M, Taddei TH, Mehta R, D’Addeo K, Dai F, Aytaman A, et al. Association of provider specialty and multidisciplinary care with hepatocellular carcinoma treatment and mortality. Gastroenterology. 2017;152:1954–64.PubMedCrossRef
5.
Kim BH, Lim YS, Kim EY, Kong HJ, Won YJ, Han S, et al. Temporal improvement in survival of patients with hepatocellular carcinoma in a hepatitis B virus-endemic population. J Gastroenterol Hepatol. 2018;33:475–83.PubMedCrossRef
6.
Cadier B, Bulsei J, Nahon P, Seror O, Laurent A, Rosa I, et al. Early detection and curative treatment of hepatocellular carcinoma: a cost-effectiveness analysis in France and in the United States. Hepatology. 2017;65:1237–48.PubMedCrossRef
7.
8.
Livraghi T, Meloni F, Di Stasi M, Rolle E, Solbiati L, Tinelli C, et al. Sustained complete response and complications rates after radiofrequency ablation of very early hepatocellular carcinoma in cirrhosis: is resection still the treatment of choice? Hepatology. 2008;47:82–9.PubMedCrossRef
9.
Nault JC, Sutter O, Nahon P, Ganne-Carrie N, Seror O. Percutaneous treatment of hepatocellular carcinoma: state of the art and innovations. J Hepatol. 2017;
10.
Marrero JA, Kulik LM, Sirlin CB, Zhu AX, Finn RS, Abecassis MM, et al. Diagnosis, staging, and management of hepatocellular carcinoma: 2018 practice guidance by the American Association for the study of liver diseases. Hepatology. 2018;68:723–50.PubMedCrossRef
11.
EASL Clinical Practice Guidelines. Management of hepatocellular carcinoma. J Hepatol. 2018;69:182–236.CrossRef
12.
KLCA-NCC Korea practice guidelines for the management of hepatocellular carcinoma. Clin Mol Hepatol. 2022;28:583–705.
13.••
Kim SY, An J, Lim YS, Han S, Lee JY, Byun JH, et al. MRI with liver-specific contrast for surveillance of patients with cirrhosis at high risk of hepatocellular carcinoma. JAMA Oncol. 2017;3:456–63. Findings from this prospective study suggest that complete gadoxetic acid-enhanced MRI outperforms US for HCC surveillance in high-risk patientsPubMedPubMedCentralCrossRef
14.
van Meer S, de Man RA, Coenraad MJ, Sprengers D, van Nieuwkerk KM, Klumpen HJ, et al. Surveillance for hepatocellular carcinoma is associated with increased survival: results from a large cohort in the Netherlands. J Hepatol. 2015;63:1156–63.PubMedCrossRef
15.
Tzartzeva K, Obi J, Rich NE, Parikh ND, Marrero JA, Yopp A, et al. Surveillance imaging and alpha fetoprotein for early detection of hepatocellular carcinoma in patients with cirrhosis: a meta-analysis. Gastroenterology. 2018;154:1706–18 e1.PubMedCrossRef
16.
Yoon JH, Lee JM, Lee DH, Joo I, Jeon JH, Ahn SJ, et al. A comparison of biannual two-phase low-dose liver CT and US for HCC surveillance in a group at high risk of HCC development. Liver Cancer. 2020;9:503–17.PubMedPubMedCentralCrossRef
17.
Son JH, Choi SH, Kim SY, Jang HY, Byun JH, Won HJ, et al. Validation of US liver imaging reporting and data system version 2017 in patients at high risk for hepatocellular carcinoma. Radiology. 2019;292:390–7.PubMedCrossRef
18.
Simmons O, Fetzer DT, Yokoo T, Marrero JA, Yopp A, Kono Y, et al. Predictors of adequate ultrasound quality for hepatocellular carcinoma surveillance in patients with cirrhosis. Aliment Pharmacol Ther. 2017;45:169–77.PubMedCrossRef
19.
Esfeh JM, Hajifathalian K, Ansari-Gilani K. Sensitivity of ultrasound in detecting hepatocellular carcinoma in obese patients compared to explant pathology as the gold standard. Clin Mol Hepatol. 2020;26:54–9.PubMedCrossRef
20.
Huang DQ, Fowler KJ, Liau J, Cunha GM, Louie AL, An JY, et al. Comparative efficacy of an optimal exam between ultrasound versus abbreviated MRI for HCC screening in NAFLD cirrhosis: a prospective study. Aliment Pharmacol Ther. 2022;55:820–7.PubMedPubMedCentralCrossRef
21.
Yang JD, Mannalithara A, Piscitello AJ, Kisiel JB, Gores GJ, Roberts LR, et al. Impact of surveillance for hepatocellular carcinoma on survival in patients with compensated cirrhosis. Hepatology. 2018;68:78–88.PubMedCrossRef
22.
Arguedas MR, Chen VK, Eloubeidi MA, Fallon MB. Screening for hepatocellular carcinoma in patients with hepatitis C cirrhosis: a cost-utility analysis. Am J Gastroenterol. 2003;98:679–90.PubMedCrossRef
23.
Goossens N, Singal AG, King LY, Andersson KL, Fuchs BC, Besa C, et al. Cost-effectiveness of risk score-stratified hepatocellular carcinoma screening in patients with cirrhosis. Clin Transl Gastroenterol. 2017;8:e101.PubMedPubMedCentralCrossRef
24•.
Kim HL, An J, Park JA, Park SH, Lim YS, Lee EK. Magnetic resonance imaging is cost-effective for hepatocellular carcinoma surveillance in high-risk patients with cirrhosis. Hepatology. 2019;69:1599–613. Findings from this study suggest that implementing risk-stratified MRI-based HCC surveillance for high-risk patients is not only superior to the currently recommended US-based surveillance but also cost-effectivePubMedCrossRef
25.
Ahn SS, Kim MJ, Lim JS, Hong HS, Chung YE, Choi JY. Added value of gadoxetic acid-enhanced hepatobiliary phase MR imaging in the diagnosis of hepatocellular carcinoma. Radiology. 2010;255:459–66.PubMedCrossRef
26.
Ueno A, Masugi Y, Yamazaki K, Komuta M, Effendi K, Tanami Y, et al. OATP1B3 expression is strongly associated with Wnt/β-catenin signalling and represents the transporter of gadoxetic acid in hepatocellular carcinoma. J Hepatol. 2014;61:1080–7.PubMedCrossRef
27.
Demirtas CO, Gunduz F, Tuney D, Baltacioglu F, Kani HT, Bugdayci O, et al. Annual contrast-enhanced magnetic resonance imaging is highly effective in the surveillance of hepatocellular carcinoma among cirrhotic patients. Eur J Gastroenterol Hepatol. 2020;32:517–23.PubMedCrossRef
28.
Reig M, Forner A, Rimola J, Ferrer-Fàbrega J, Burrel M, Garcia-Criado Á, et al. BCLC strategy for prognosis prediction and treatment recommendation: the 2022 update. J Hepatol. 2022;76:681–93.PubMedCrossRef
29.
Kim YK, Lee WJ, Park MJ, Kim SH, Rhim H, Choi D. Hypovascular hypointense nodules on hepatobiliary phase gadoxetic acid-enhanced MR images in patients with cirrhosis: potential of DW imaging in predicting progression to hypervascular HCC. Radiology. 2012;265:104–14.PubMedCrossRef
30.
Piana G, Trinquart L, Meskine N, Barrau V, Beers BV, Vilgrain V. New MR imaging criteria with a diffusion-weighted sequence for the diagnosis of hepatocellular carcinoma in chronic liver diseases. J Hepatol. 2011;55:126–32.PubMedCrossRef
31.
Vandecaveye V, De Keyzer F, Verslype C, Op de Beeck K, Komuta M, Topal B, et al. Diffusion-weighted MRI provides additional value to conventional dynamic contrast-enhanced MRI for detection of hepatocellular carcinoma. Eur Radiol. 2009;19:2456–66.PubMedCrossRef
32.
Kim HJ, Lee SS, Byun JH, Kim JC, Yu CS, Park SH, et al. Incremental value of liver MR imaging in patients with potentially curable colorectal hepatic metastasis detected at CT: a prospective comparison of diffusion-weighted imaging, gadoxetic acid–enhanced MR imaging, and a combination of both MR techniques. Radiology. 2015;274:712–22.PubMedCrossRef
33.
Brunsing RL, Chen DH, Schlein A, Wolfson T, Gamst A, Mamidipalli A, et al. Gadoxetate-enhanced abbreviated MRI for hepatocellular carcinoma surveillance: preliminary experience. Radiol Imaging Cancer. 2019;1:e190010.PubMedPubMedCentralCrossRef
34.
Vietti Violi N, Lewis S, Liao J, Hulkower M, Hernandez-Meza G, Smith K, et al. Gadoxetate-enhanced abbreviated MRI is highly accurate for hepatocellular carcinoma screening. Eur Radiol. 2020;30:6003–13.PubMedCrossRef
35.
An JY, Pena MA, Cunha GM, Booker MT, Taouli B, Yokoo T, et al. Abbreviated MRI for hepatocellular carcinoma screening and surveillance. Radiographics. 2020;40:1916–31.PubMedCrossRef
36.
37.
Barth M, Breuer F, Koopmans PJ, Norris DG, Poser BA. Simultaneous multislice (SMS) imaging techniques. Magn Reson Med. 2016;75:63–81.PubMedCrossRef
38.
Taron J, Martirosian P, Erb M, Kuestner T, Schwenzer NF, Schmidt H, et al. Simultaneous multislice diffusion-weighted MRI of the liver: analysis of different breathing schemes in comparison to standard sequences. J Magn Reson Imaging. 2016;44:865–79.PubMedCrossRef
39.
Obele CC, Glielmi C, Ream J, Doshi A, Campbell N, Zhang HC, et al. Simultaneous multislice accelerated free-breathing diffusion-weighted imaging of the liver at 3T. Abdom Imaging. 2015;40:2323–30.PubMedCrossRef
40.
Kim JY, Lee SS, Byun JH, Kim SY, Park SH, Shin YM, et al. Biologic factors affecting HCC conspicuity in hepatobiliary phase imaging with liver-specific contrast agents. AJR Am J Roentgenol. 2013;201:322–31.PubMedCrossRef
41.
Kim SY, Wu EH, Park SH, Wang ZJ, Hope TA, Yee J, et al. Comparison of hepatocellular carcinoma conspicuity on hepatobiliary phase images with gadoxetate disodium vs. delayed phase images with extracellular cellular contrast agent. Abdom Radiol (NY). 2016;41:1522–31.PubMedPubMedCentralCrossRef
42.
Park HJ, Seo N, Kim SY. Current landscape and future perspectives of abbreviated MRI for hepatocellular carcinoma surveillance. Korean J Radiol. 2022;23:598–614.PubMedPubMedCentralCrossRef
43.
Marks RM, Ryan A, Heba ER, Tang A, Wolfson TJ, Gamst AC, et al. Diagnostic per-patient accuracy of an abbreviated hepatobiliary phase gadoxetic acid-enhanced MRI for hepatocellular carcinoma surveillance. AJR Am J Roentgenol. 2015;204:527–35.PubMedCrossRef
44.
Tillman BG, Gorman JD, Hru JM, Lee MH, King MC, Sirlin CB, et al. Diagnostic per-lesion performance of a simulated gadoxetate disodium-enhanced abbreviated MRI protocol for hepatocellular carcinoma screening. Clin Radiol. 2018;73:485–93.PubMedCrossRef
45•.
Park HJ, Kim SY, Singal AG, Lee SJ, Won HJ, Byun JH, et al. Abbreviated magnetic resonance imaging vs ultrasound for surveillance of hepatocellular carcinoma in high-risk patients. Liver Int. 2021;42:2080–92. This study demonstrates the potential of abbreviated MRI-based approach for HCC surveillance in high-risk patients, as it exhibits higher sensitivity compared to ultrasoundPubMedCrossRef
46.
Park HJ, Jang HY, Kim SY, Lee SJ, Won HJ, Byun JH, et al. Non-enhanced magnetic resonance imaging as a surveillance tool for hepatocellular carcinoma: comparison with ultrasound. J Hepatol. 2020;72:718–24.PubMedCrossRef
47.
Ahmed NNA, El Gaafary SM, Elia RZ, Abdulhafiz EM. Role of abbreviated MRI protocol for screening of HCC in HCV related cirrhotic patients prior to direct-acting antiviral treatment. Egypt J Radiol Nucl Med. 2020;51:102.CrossRef
48.
Sutherland T, Watts J, Ryan M, Galvin A, Temple F, Vuong J, et al. Diffusion-weighted MRI for hepatocellular carcinoma screening in chronic liver disease: direct comparison with ultrasound screening. J Med Imaging Radiat Oncol. 2017;61:34–9.PubMedCrossRef
49.
Choi MH, Choi JI, Yoon JH, et al. Annual non-contrast liver MRI versus biannual liver ultrasonography for surveillance of HCC in patients with liver cirrhosis (MAGNUS-HCC): results of a prospective, multicenter trial (abstract). In: Proceedings of the 76th Annual Meeting of the Korean Congress of Radiology and Annual Delegate Meeting of The Korean Society of Radiology; September 17-19, 2020.
50.
Gupta P, Soundararajan R, Patel A, Kumar MP, Sharma V, Kalra N. Abbreviated MRI for hepatocellular carcinoma screening: a systematic review and meta-analysis. J Hepatol. 2021;75:108–19.PubMedCrossRef
51.
Besa C, Lewis S, Pandharipande PV, Chhatwal J, Kamath A, Cooper N, et al. Hepatocellular carcinoma detection: diagnostic performance of a simulated abbreviated MRI protocol combining diffusion-weighted and T1-weighted imaging at the delayed phase post gadoxetic acid. Abdom Radiol (NY). 2017;42:179–90.PubMedCrossRef
52.
Whang S, Choi MH, Choi JI, Youn SY, Kim DH, Rha SE. Comparison of diagnostic performance of non-contrast MRI and abbreviated MRI using gadoxetic acid in initially diagnosed hepatocellular carcinoma patients: a simulation study of surveillance for hepatocellular carcinomas. Eur Radiol. 2020;30:4150–63.PubMedCrossRef
53.
Joo I, Kim SY, Kang TW, Kim YK, Park BJ, Lee YJ, et al. Radiologic-pathologic correlation of hepatobiliary phase hypointense nodules without arterial phase hyperenhancement at gadoxetic acid–enhanced MRI: a multicenter study. Radiology. 2020;296:335–45.PubMedCrossRef
54.
Joo I, Lee JM, Lee DH, Jeon JH, Han JK, Choi BI. Noninvasive diagnosis of hepatocellular carcinoma on gadoxetic acid-enhanced MRI: can hypointensity on the hepatobiliary phase be used as an alternative to washout? Eur Radiol. 2015;25:2859–68.PubMedCrossRef
55.
56.
57.
Park SH, Kim B, Kim SY, Shim YS, Kim JH, Huh J, et al. Abbreviated MRI with optional multiphasic CT as an alternative to full-sequence MRI: LI-RADS validation in a HCC-screening cohort. Eur Radiol. 2020;30:2302–11.PubMedCrossRef
58.
Brismar TB, Dahlstrom N, Edsborg N, Persson A, Smedby O, Albiin N. Liver vessel enhancement by Gd-BOPTA and Gd-EOB-DTPA: a comparison in healthy volunteers. Acta Radiol. 2009;50:709–15.PubMedCrossRef
59.
Tamada T, Ito K, Sone T, Yamamoto A, Yoshida K, Kakuba K, et al. Dynamic contrast-enhanced magnetic resonance imaging of abdominal solid organ and major vessel: comparison of enhancement effect between Gd-EOB-DTPA and Gd-DTPA. J Magn Reson Imaging. 2009;29:636–40.PubMedCrossRef
60.
Davenport MS, Viglianti BL, Al-Hawary MM, Caoili EM, Kaza RK, Liu PS, et al. Comparison of acute transient dyspnea after intravenous administration of gadoxetate disodium and gadobenate dimeglumine: effect on arterial phase image quality. Radiology. 2013;266:452–61.PubMedCrossRef
61.
Kim DW, Choi SH, Park T, Kim SY, Lee SS, Byun JH. Transient severe motion artifact on arterial phase in gadoxetic acid–enhanced liver magnetic resonance imaging: a systematic review and meta-analysis. Invest Radiol. 2021;
62.
Huh J, Kim SY, Yeh BM, Lee SS, Kim KW, Wu EH, et al. Troubleshooting arterial-phase MR images of gadoxetate disodium-enhanced liver. Korean J Radiol. 2015;16:1207–15.PubMedPubMedCentralCrossRef
63.
64.
Levine D, McDonald RJ, Kressel HY. Gadolinium retention after contrast-enhanced MRI. JAMA. 2018;320:1853–4.PubMedCrossRef
65.
Lee JY, Huo EJ, Weinstein S, Santos C, Monto A, Corvera CU, et al. Evaluation of an abbreviated screening MRI protocol for patients at risk for hepatocellular carcinoma. Abdom Radiol (NY). 2018;43:1627–33.PubMedPubMedCentralCrossRef
66.
67.
Khatri G, Pedrosa I, Ananthakrishnan L, de Leon AD, Fetzer DT, Leyendecker J, et al. Abbreviated-protocol screening MRI vs. complete-protocol diagnostic MRI for detection of hepatocellular carcinoma in patients with cirrhosis: an equivalence study using LI-RADS v2018. J Magn Reson Imaging. 2020;51:415–25.PubMedCrossRef
68.
69.
Chernyak V, Fowler KJ, Kamaya A, Kielar AZ, Elsayes KM, Bashir MR, et al. Liver Imaging Reporting and Data System (LI-RADS) version 2018: imaging of hepatocellular carcinoma in at-risk patients. Radiology. 2018;289:816–30.PubMedCrossRef
70.
Park SH, Kim B, Kim SY, Choi SJ, Huh J, Kim HJ, et al. Characterizing computed tomography-detected arterial hyperenhancing-only lesions in patients at risk of hepatocellular carcinoma: can non-contrast magnetic resonance imaging be used for sequential imaging? Korean J Radiol. 2020;21:280–9.PubMedPubMedCentralCrossRef
71.
72.
El-Serag HB, Rudolph KL. Hepatocellular carcinoma: epidemiology and molecular carcinogenesis. Gastroenterology. 2007;132:2557–76.PubMedCrossRef
73.
Wong LL, Reyes RJ, Kwee SA, Hernandez BY, Kalathil SC, Tsai NC. Pitfalls in surveillance for hepatocellular carcinoma: how successful is it in the real world? Clin Mol Hepatol. 2017;23:239–48.PubMedPubMedCentralCrossRef
Metadata
Title
Magnetic Resonance Imaging-Based Surveillance of Hepatocellular Carcinoma: Current Status and Future Perspectives
Authors
Hyo Jung Park
So Yeon Kim
Young-Suk Lim
Publication date
15-07-2023
Publisher
Springer US
Published in
Current Hepatology Reports / Issue 3/2023
Electronic ISSN: 2195-9595
DOI
https://doi.org/10.1007/s11901-023-00611-w

Other articles of this Issue 3/2023

Current Hepatology Reports 3/2023 Go to the issue

ReviewPaper

An Overview of the Therapeutic Development of Cholangiocarcinoma with Special Emphasis on Targeted and Biologic Therapies

ReviewPaper

Management of Portal Biliopathy

ReviewPaper

Non-invasive Assessment of Clinically Significant Portal Hypertension

ReviewPaper

Management of Immune-Tolerant Patients with Chronic HBV Infection

ReviewPaper

Current and Evolving Management of Chronic Hepatitis Delta Virus (HDV) Infection

ReviewPaper

Nodular Regenerative Hyperplasia
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits